Valeant chops workforce in restructuring

In an effort to bring expenses in line with revenues, Valeant is cutting 130 workers in the U.S. and Mexico. In addition, headcount will be further reduced by 1,250 positions as it divests its European subsidiaries. The full effects of the layoffs will be felt within the next year. The layoffs will reduce Valean's staff by about half.

"This is the first step in our plan to right size our company and return it to appropriate levels of profitability," said J. Michael Pearson, chairman and chief executive officer. "We understand the impact these changes will have on our employees and we are committed to treating everyone with respect and dignity. While difficult, these changes are in the best interest of the company to generate meaningful change that will produce long-term value."

- here's Valeant's release

Related Articles:
Valeant shares jump on epilepsy trial data
Valeant sells development programs
Valeant hep C drug fails pivotal trial, again
Valeant to out-license programs in restructuring

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.